Sensus Healthcare, Inc. — Q1 2019 Form 10-Q
Business context and reporting period. The company manufactures radiation-therapy devices, including the SRT-100 product line, and related services. It reports one operating segment. This unaudited quarterly report covers the three months ended March 31, 2019; comparisons are with Q1 2018 unless otherwise noted.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $5.44 million | $5.96 million; down 8.7% |
| Gross profit / margin | $3.32 million / 61.0% | $3.94 million / 66.2% |
| Operating expenses | $5.51 million | $5.05 million |
| Operating loss | $2.19 million | $1.11 million |
| Net loss | $2.12 million; $0.13 per diluted share | $1.13 million; $0.08 per diluted share |
| Cash used in operating activities | $7.12 million | $3.48 million |
Product revenue was $4.93 million, down from $5.53 million; service revenue was $506,000, up from $423,000. Cash and cash equivalents were $6.25 million at March 31, 2019, and short-term debt securities were $4.70 million, for combined cash and investments of approximately $10.95 million, versus $15.38 million at year-end 2018. Current assets were $31.64 million and current liabilities $5.20 million. Total liabilities were $6.53 million, including operating lease liabilities; no revolving-credit borrowings were outstanding. The company reported total stockholders’ equity of $27.20 million.
Material changes and management commentary
- Management attributed lower revenue primarily to reduced sales of the higher-priced SRT-100 Vision. Cost of sales rose 5.2%, and gross margin declined mainly because of product mix.
- Selling and marketing expense rose 14.2%, primarily due to increased headcount. Research and development expense rose 31.2%, which management linked to Sculptura FDA clearance and ramping production. General and administrative expense fell 24.5%, primarily reflecting lower stock-compensation expense.
- Operating cash use increased, with the filing citing a $3.7 million rise in accounts receivable, associated with longer payment terms for a key customer, as a major working-capital factor. Financing cash inflow of $2.70 million came from warrant exercises; investing cash use was $1.82 million, mostly net purchases of held-to-maturity debt securities.
- The company received FDA clearance for Sculptura, a robotic radiation oncology system, in February 2019. It also adopted the new lease accounting standard, recognizing approximately $805,000 of right-of-use assets and lease liabilities at adoption; management said adoption did not materially affect liquidity, results, or credit-facility covenant compliance.
Outlook, risks, and contingencies
The filing provides no specific revenue, earnings, or cash-flow guidance. Management said liquidity and capital needs depend on revenue generation, margins, expenses, working capital, and planned sales, marketing, distribution, and R&D activity; it may seek additional funds in the future. The $5 million revolving facility, secured by company assets, matures October 31, 2019, and requires compliance with a monthly adjusted quick-ratio covenant; the company reported compliance at March 31, 2019.
Key disclosed risks include the ability to achieve profitability and commercialize products, reimbursement and regulatory conditions, reliance on third-party manufacturers and suppliers, and dependence on major customers. One U.S. customer represented approximately 53% of Q1 revenue and 87% of accounts receivable at March 31, 2019. The U.S. accounted for approximately 81% of Q1 revenue. A Department of Justice investigation related to a physician’s Medicare billing remains unresolved; the company disputes wrongdoing and cannot estimate associated costs. The company also disclosed a new 10-year Israeli manufacturing-facility lease, with specified termination options. Its 2,037,719 outstanding warrants had an exercise price of $6.75 and a stated exercisability period through June 2, 2019. Management reported no material changes to previously disclosed risk factors, effective disclosure controls, and no subsequent events requiring disclosure.
Investor verification points
- Assess whether the revenue decline and gross-margin contraction were temporary or reflect sustained product-mix or demand changes.
- Track collections from the concentrated key customer, accounts-receivable aging, and the effect of extended payment terms on cash use.
- Review subsequent cash, investment, and operating-cash-flow trends against the Q1 decline in liquidity.
- Verify the status and terms of the revolving facility at its October 2019 maturity, and the outcome of the DOJ matter.
- Check Sculptura commercialization, production ramp, and related spending, along with the utilization and cost implications of the Israeli facility lease.
- Confirm the outcome and dilution effects of warrants exercisable through June 2, 2019.